Ucwaningo lwe-MK-0616 lwemiphumela yenhliziyo nemithambo yegazi

Lesi isifundo sesigaba sesi-3, esingahleliwe, esilawulwa yi-placebo sokusebenza nokuphepha kwe-enlicitide decanoate, i-oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, kubahlanganyeli abasengozini enkulu yenhliziyo nemithambo yegazi. Inhloso eyinhloko ukuhlola ukusebenza kahle kwe-enlicitide decanoate uma kuqhathaniswa ne-placebo ekwandiseni isikhathi sokuvela kokuqala kwezehlakalo ezimbi kakhulu zenhliziyo nemithambo yegazi (MACE) okuhlanganisa ukufa kwe-coronary heart disease (CHD), ischemic stroke, myocardial infarction (MI), i-acute limb ischemia noma ukunqunywa okukhulu kwemithambo, noma ukuvuselelwa kabusha kwemithambo ephuthumayo.